Raymond James removed Boston Scientific (BSX) from the firm’s “Analyst Current Favorites” list while keeping a Strong Buy rating on the shares with a $91 price target. The firm believes upside to its estimates still exists but sees more near-term appreciation potential in shares of DexCom (DXCM), a stock it added to the “Analyst Current Favorites” list.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $91 from $85 at Raymond James
- Boston Scientific price target raised to $78 from $73 at Deutsche Bank
- Boston Scientific price target raised to $88 from $83 at Canaccord
- Boston Scientific price target raised to $91 from $90 at Baird
- Unusually active option classes on open July 24th